Literature DB >> 10225710

Leukocyte removal filter-passed lymphocytes produce large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease: role of bystander suppression.

M Noguchi1, N Hiwatashi, T Hayakawa, T Toyota.   

Abstract

To determine immunosuppression by leukocytapheresis, we studied the immune profiles of filter-passed lymphocytes (FPLs) in patients with ulcerative colitis. These patients were treated with a leukocytapheresis (LCAP) filter of granulocyte apheresis (GCAP) column. Cytokine profiles or FPLs and peripheral blood mononuclear cells (PBMCs) were examined using interleukin (IL)-4 and interferon-gamma (IFN-gamma) immunoassay with lectin stimulation. The IL-4 production of LCAP FPLs was significantly higher than in prefilter PBMCs and GCAP column-passed lymphocytes (median: 540 pg/ml x 10(6) cells versus 4.7 and 2.9, respectively, p = 0.001). IL-4 production in PBMCs was increased after LCAP. IFN-gamma production was not increased in the FPLs. The IL-4 immune deviation was not shown in the patients treated with GCAP. LCAP FPLs showed increased CD4+DR- cells and decreases CD4+DR+ cells in comparison to PBMCs. LCAP FPLs could produce IL-4 and may lead to bystander suppression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10225710     DOI: 10.1111/j.1744-9987.1998.tb00086.x

Source DB:  PubMed          Journal:  Ther Apher        ISSN: 1091-6660


  10 in total

1.  Leukocyte removal therapy before surgery in ulcerative colitis.

Authors:  Toshiyuki Matsui
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

2.  Clinical effectiveness of selective granulocyte, monocyte adsorptive apheresis with the Adacolumn device in ulcerative colitis.

Authors:  Brigitte Habermalz; Stefan Sauerland
Journal:  Dig Dis Sci       Date:  2009-06-11       Impact factor: 3.199

Review 3.  Immunological Mechanisms of Adsorptive Cytapheresis in Inflammatory Bowel Disease.

Authors:  Esteban Sáez-González; Inés Moret; Diego Alvarez-Sotomayor; Francia Carolina Díaz-Jaime; Elena Cerrillo; Marisa Iborra; Pilar Nos; Belén Beltrán
Journal:  Dig Dis Sci       Date:  2017-04-21       Impact factor: 3.199

4.  Leukocytapheresis: An "Out-of-Body" Experience in Inflammatory Bowel Disease.

Authors:  Seymour Katz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-12

5.  Cytapheresis as a Non-Pharmacological Therapy for Inflammatory Bowel Disease.

Authors:  Takayuki Matsumoto; Ken Fukunaga; Koji Kamikozuru; Katsutoshi Tozawa; Yoko Yokoyama; Takeshi Kusaka; Kunio Onishi; Hiroto Miwa; Shiro Nakamura
Journal:  Transfus Med Hemother       Date:  2007-12-21       Impact factor: 3.747

6.  Decrease of reactive-oxygen-producing granulocytes and release of IL-10 into the peripheral blood following leukocytapheresis in patients with active ulcerative colitis.

Authors:  Hiroyuki Hanai; Takayuki Iida; Ken Takeuchi; Fumitoshi Watanabe; Yasuhiko Maruyama; Masataka Kikuyama; Tatsuo Tanaka; Kenji Kondo; Kou Tanaka; Kenji Takai
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

7.  Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients.

Authors:  Ken Fukunaga; Yoshihiro Fukuda; Yoko Yokoyama; Kunio Ohnishi; Takeshi Kusaka; Tadashi Kosaka; Nobuyuki Hida; Yoshio Ohda; Hiroto Miwa; Takayuki Matsumoto
Journal:  J Gastroenterol       Date:  2006-06       Impact factor: 7.527

8.  Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis.

Authors:  Yuhki Yagi; Akira Andoh; Osamu Inatomi; Shigeki Bamba; Tomoyuki Tsujikawa; Yoshihide Fujiyama; Keiichi Mitsuyama; Takashi Yoshida
Journal:  J Gastroenterol       Date:  2006-06       Impact factor: 7.527

Review 9.  Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis.

Authors:  Takayuki Yamamoto; Satoru Umegae; Koichi Matsumoto
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

10.  Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis--results of a randomized pilot trial.

Authors:  Jörg Emmrich; Sebastian Petermann; Dietrich Nowak; Ingolf Beutner; Peter Brock; Reinhard Klingel; Patrick Mausfeld-Lafdhiya; Stefan Liebe; Wolfgang Ramlow
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.